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Background: The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis
(XDR-TB) makes the treatment and control of tuberculosis difficult. Rapid detection of drug-resistant strains is important
for the successful treatment of drug-resistant tuberculosis; however, not all resistance mechanisms to the injectable
second-line drugs such as amikacin (AK), kanamycin (KM), and capreomycin (CAP) are well understood. This study aims
to validate the mechanisms associated with AK, KM, and CAP resistance in M. tuberculosis clinical strains isolated in
Thailand.
Results: A total of 15,124M. tuberculosis clinical strains were isolated from 23,693 smear-positive sputum samples
sent from 288 hospitals in 46 of 77 provinces of Thailand. Phenotypic analysis identified 1,294 strains as MDR-TB
and second-line drugs susceptibility was performed in all MDR-TB strains and revealed 58 XDR-TB strains. Twenty-nine
KM-resistant strains (26 XDR-TB and 3 MDR-TB) could be retrieved and their genes associated with AK, KM, and CAP
resistance were investigated compared with 27 KM-susceptible strains. Mutation of the rrs (A1401G) was found in 21
out of 29 KM-resistant strains whereas mutations of eis either at C-14 T or at G-37 T were found in 5 strains. Three
remaining KM-resistant strains did not contain any known mutations. Capreomycin resistance was determined in 28
of 29 KM-resistant strains. Analysis of tlyA revealed that the A33G mutation was found in all CAP-resistant strains and
also in susceptible strains. In contrast, the recently identified tlyA mutation T539G and the novel Ins49GC were found
in two and one CAP-resistant strains, respectively. In addition, our finding demonstrated the insertion of cytosine at
position 581 of the tap, a putative drug efflux encoding gene, in both KM-resistant and KM-susceptible strains.
Conclusions: Our finding demonstrated that the majority of KM resistance mechanism in Thai M. tuberculosis clinical
strains was rrs mutation at A1401G. Mutations of the eis promoter region either at C-14 T or G-37 T was found in 5
of 29 strains whereas three strains did not contain any known mutations. For CAP resistance, 3 of 28 CAP-resistant
strains contained either T539G or Ins49GC mutations at tlyA that might be associated with the resistant phenotype.
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Tuberculosis (TB) is a global public health problem
caused by an infection with Mycobacterium tuberculosis.
There were approximately 9 million new cases of TB
and 1.3 million deaths in 2012 [1]. The emergence of
multidrug-resistant TB (MDR-TB; resistance at least
to isoniazid and rifampicin) and extensively drug-
resistant TB (XDR-TB; MDR-TB plus resistance to any* Correspondence: kpsarany@kmitl.ac.th
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article, unless otherwise stated.fluoroquinolones and one of the second-line injectable
drugs, amikacin, kanamycin and capreomycin) remains
a global health problem that hinders the prevention,
treatment, and control of TB. In Thailand, approximately
80,000 new TB cases were notified in 2012 and MDR-TB
appeared in 1.7% and 35% of new TB cases and previously
treated TB cases, respectively [1].
Rapid identification of drug-resistant strains is one of
the major strategies for fighting against TB. Molecular-
based methods for detection of drug resistance genes
have been shown to be a promising method for identifi-
cation of drug-resistant strains; for example, the XpertCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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have been successfully used to identify rifampicin-resistant
M. tuberculosis and MDR-TB, respectively [2-7]. In con-
trast, knowledge concerning resistance mechanisms of the
second-line anti-TB drugs is still limited. Better under-
standing of the resistance mechanisms of these drugs could
lead to the development of a high sensitive test for detec-
tion of the resistance genes and also promote the use of
molecular-based methods for screening the strains resist-
ant to second-line drugs, including the XDR-TB strain.
The aminoglycosides amikacin (AK) and kanamycin
(KM) are the second-line injectable drugs used to treat
MDR-TB. The drugs bind to 16S rRNA in the 30S small
ribosomal subunit and inhibit protein synthesis [8]. Mu-
tations in the rrs gene encoding 16S rRNA are associ-
ated with high-level drug resistance in M. tuberculosis;
the rrs A1401G mutation is the most frequently reported
mutation and has been identified in 30 to 90% of KM-
resistant M. tuberculosis strains [9-12].
Recently, overexpression of the aminoglycoside
acetyltransferase-encoding gene, eis, has been associated
with a low-level resistance to KM [13,14]. This overex-
pression resulted from either point mutations in the
promoter region of the eis gene or mutations in the
5′ untranslated region (UTR) of the whiB7 gene, which
encodes a putative regulator of the eis gene. This type of
eis promoter mutation was found in 26-80% of KM-
resistant M. tuberculosis clinical strains [14-17]. However,
some resistant strains do not contain any known muta-
tions. Other possible resistance mechanisms, including
the presence of drug efflux pumps or enzymes that can
inactivate the drug or modify the drug target, have been
proposed. Tap, a putative efflux pump that was originally
described in Mycobacterium fortuitum, conferred resist-
ance to tetracycline and aminoglycosides when intro-
duced into M. smegmatis [18]. A homolog of this protein
(Rv1258c) has been found in M. tuberculosis and func-
tions under the control of WhiB7 [19].
Previous studies demonstrated that the rrs mutation
conferring KM resistance also exhibited the cross-
resistance to capreomycin (CAP), a cyclic polypeptide
antibiotic [20,21]. Capreomycin binds across the 23S
rRNA helix 69 and 16S rRNA helix 44 of the ribosome,
resulting in inhibiting the protein synthesis [22,23]. Re-
sistance to CAP has been reported to correlate with
the gene encoding 2´-O-methyltransferase (tlyA) [24],
although it is not a sensitive genetic marker for CAP
resistance due to the infrequent finding [16]. TlyA func-
tions by methylating at nucleotide C1409 in helix 44 of
16S rRNA and nucleotide C1920 in helix 69 of 23S rRNA.
Loss of this methylation confers resistance to CAP and
viomycin [23].
The present study aimed to validate all reported mech-
anisms associated with AK, KM and CAP resistance inM/XDR-TB clinical strains isolated in Thailand. More-
over, these mechanisms were also investigated in KM–
susceptible strains.
Results
Amikacin- and kanamycin-resistant phenotypes
A total of 15,124M. tuberculosis clinical strains were iso-
lated from 23,693 smear-positive sputum samples sent
from 288 hospitals in 46 of 77 provinces of Thailand.
Phenotypic analysis identified 1,294 strains as MDR-TB.
Using the standard proportion method on M7H10 agar
with a single concentration of 1 μg/ml for ofloxacin and
6 μg/ml for AK and KM, 58 strains were defined as
XDR-TB. Twenty-nine KM-resistant strains (26 XDR-TB
and 3 MDR-TB) could be retrieved and available for fur-
ther investigation on the genes associated with AK, KM,
and CAP resistance (Additional file 1: Table S1). MICs
of AM, KM, and CAP were determined, and the results
are summarized in Table 1.
Molecular analysis of genes associated with amikacin,
kanamycin, and capreomycin resistance
The 16S rRNA genes (rrs) of all 29 KM-resistant strains
were amplified and sequenced. The results revealed a
point mutation at nucleotide position 1401 (A→G),
which corresponds to position 1408 of the Escherichia
coli rrs gene, in 21 strains (Table 1). Almost all strains
harboring the rrs A1401G mutation showed a high-level
of resistance to both AK and KM, with MICs >64 μg/ml,
whereas variable MICs were found against CAP, with
ranging from 4 to >64 μg/ml (Table 1).
The nucleotide sequences of coding regions and the
putative promoter regions of eis (Rv2416c) and whiB7
(Rv3197A), coding regions of tap (Rv1258c) and tlyA
(Rv1694), were investigated in all KM-resistant clinical
strains and 27 KM-susceptible clinical strains. No muta-
tion of all investigated genes (except for tap) was found
in 21 strains with rrs mutation. For the remaining
eight KM-resistant strains, point mutations at either
position -14 (C→T) or position -37 (G→T) upstream of
the eis gene were observed in 5 strains; the C-14 T muta-
tion was found in 4 strains, whereas the G-37 T mutation
was found in only one strain (Table 1 and Additional
file 1: Table S1). No eis mutations were found in 27
KM-susceptible strains (Table 1 and Additional file 2:
Table S2). Sequence analysis of the whiB7 gene and its
promoter region did not reveal any mutations in all KM-
resistant and -susceptible strains (Table 1).
Investigation of the tap gene in KM-resistant strains
revealed that almost all strains (except one strain) with
Beijing genotype exhibited the insertion of cytosine be-
tween position 580 and 581 of the tap gene (Additional
file 1: Table S1). This insertion caused a frameshift mu-
tation and a premature stop codon, resulting in the
Table 1 Genetic characterization of genes associated with KM resistance of KM-resistant and KM-susceptible
M. tuberculosis strains
No. of strains MIC (μg/ml) Gene/Mutation
AK KM CAP rrs eis tap whiB7 tlyA
KM resistant (29)
1 >64 >64 >64 A1401G wt Ins581C wt A33Gb
7 >64 >64 32 A1401G wt Ins581C wt A33Gb
5 >64 >64 32 A1401G wt wt wt A33Gb
4a >64 >64 16 A1401G wt Ins581C wt A33Gb
2 >64 >64 16 A1401G wt wt wt A33Gb
1 >64 >64 4 A1401G wt Ins581C wt A33Gb
1 8 32 8 A1401G wt Ins581C wt A33Gb
1 8 >64 8 wt C-14 T Ins581C wt A33Gb
1 8 >64 >64 wt C-14 T Ins581C wt A33Gb/Ins49GC
2a 8 >64 >64 wt C-14 T Ins581C wt A33Gb/T539G
1 8 >64 >64 wt G-37 T Ins581C wt A33Gb
2 >64 >64 16 wt wt Ins581C wt A33Gb
1a >64 >64 16 wt wt wt wt A33Gb
KM susceptible (27)
5 2-4 4 2-4 wt wt Ins581C wt A33Gb
22 2-4 4 2-4 wt wt wt wt A33Gb
ainclude one MDR-TB strain; bno amino acid change.
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419 to 231 amino acids). However, analysis of KM-
susceptible strains also revealed this mutation (5 out of
27 strains) (Table 1 and Additional file 2: Table S2).
Sequence analysis of the tlyA gene revealed A→G nu-
cleotide substitution at position 33 in all KM-resistant
strains; however this mutation did not confer any amino
acid change (Table 1 and Additional file 1: Table S1).
Two CAP-resistant strains showed the T→G nucleotide
substitution at position 539 of tlyA that caused the
amino acid change from lysine to arginine (L→ R) at
codon 180 (Additional file 1: Table S1). One strain
showed an insertion of GC at position 49, resulting in a
frameshift mutation and the reduction of amino acid size
from 268 to 26 amino acids (Additional file 1: Table S1).
However, the A33G mutation, but not other tlyA muta-
tions, was also found in all susceptible strains (Table 1
and Additional file 2: Table S2).
Discussion
In this study, the genetic mutations associated with re-
sistance to AK, KM, and CAP were investigated in 26
XDR- and 3 MDR-TB strains isolated in Thailand. A
nucleotide substitution from A to G at position 1401
(corresponding to position 1408 of the E. coli rrs gene) of
the rrs gene is the most common mutation conferring
high-level resistance to AK and KM in M. tuberculosis.Although approximately 30-90% of resistant strains con-
tain this mutation [9-12], other mutations, including
C1402T and G1484T, have also been reported [25-29].
The A1401G mutation has been preferentially used as a
surrogate marker for resistance to AK and KM, whereas
other rrs mutations are poor markers due to their pres-
ence in susceptible strains [30]. Our results revealed that
the A1401G mutation was present in 21 of 29 KM-
resistant clinical strains, and no other rrs mutations were
identified (Table 1). Almost all of these strains (20 out
of 21) had MICs >64 μg/ml for both AK and KM while
they showed broad MICs ranging from 4 to 64 μg/ml for
CAP. This is consistent with previous studies reporting
that the rrs A1401G mutation is the most common
mechanism of KM resistance and correlates with high-
level resistance [21,31,32]. In addition, this mutation also
confers cross-resistance to CAP [31]. The eight KM-
resistant strains lacking the rrs mutation showed high-
level resistance to KM (MIC >64 μg/ml), but five of them
had a lower MIC for AK (MIC of 8 μg/ml), indicating
that other resistance determinants are involved in their
resistance phenotype.
Investigation of other reported resistance mechanisms
revealed that five of them had mutations in the pro-
moter region of the eis gene, which encodes an amino-
glycoside acetyltransferase (Table 1). This aminoglycoside
acetyltransferase (Eis) catalyzes the transfer of an acetyl
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aminoglycoside. It has been reported that Eis of M. tuber-
culosis shows a multiacetylation capability at the 2′-, 3-
or 6′ positions of aminoglycoside antibiotics, resulting in
an inactivation of many aminoglycoside antibiotics, in-
cluding neamine, hygromycin, kanamycin, and amikacin
[33]. In this study, all five strains harboring eis promoter
mutations showed high-level KM resistance but low-
level resistance to AK. The most identified mutation
was C-14 T (4 of 5 strains). These mutations and other
eis mutations, such as G-6 T, G-10A, C-12 T, A-13G and
C-15 T, have been previously shown to be associated with
KM resistance [14,16,17]. Zaunbrecher et al. (2009) have
reported that the major eis promoter mutations were
G-10A and C-14 T [14]. Overexpression of eis resulting
from the C-14 T mutation caused the highest levels of eis
transcript, followed by G-37 T, G-10A, C-12 T and A-13G
mutations [14]. In contrast to the previous study indicat-
ing that overexpression of eis confers low-level resistance
to KM [14], our results revealed that the strains harboring
eis mutation expressed high-level resistance to KM. One
possible explanation is that these strains have additional
unknown mechanisms contributing to their KM resist-
ance, and these generate high-level resistance in combin-
ation with the eis mutation.
Other resistance determinants that are thought to be
involved in resistance to AK, KM, and other structurally
unrelated aminoglycosides (i.e., streptomycin) were also
investigated in this study. The Tap protein is a putative
multidrug efflux pump that was originally described in
M. fortuitum [18]. Rv1258c encodes the homologous
Tap protein in M. tuberculosis. Introduction of the tap
gene from M. fortuitum into M. smegmatis conferred
low-level resistance to tetracycline and aminoglycosides
[18,34,35]. Our results revealed an insertion of cytosine
between positions 580 and 581 of tap in 21 of 29 KM-
resistant strains. This mutation leads to a frameshift
mutation at codon 194 resulting in the production of
a truncated protein, reduced in size from 419 to 231
amino acids, that is likely to affect Tap activity. However,
this insertion was also found in KM-susceptible clinical
strains, suggesting that this protein is not associated
with AK and KM resistance in M. tuberculosis. Interest-
ingly, all of these tap mutation was found in the Beijing
strains. This result was consistent with recent studies
demonstrated that this type of mutation was found in all
M. tuberculosis Beijing strains isolated from Russia, South
Africa, the United Kingdom, and Spain [36,37] and con-
firmed the observation that an insertion of cytosine be-
tween positions 580 and 581 of tap is a polymorphism
specific to the Beijing family of M. tuberculosis [37].
An association of WhiB7, a transcriptional regulator,
with the expression of at least two antibiotic resistance
genes, eis and tap has been demonstrated [19]. An increasein whiB7 expression, resulting from mutations located in
the 5′ untranslated region (UTR), leads to upregulation of
eis and tap, conferring low-level resistance to KM and
streptomycin, respectively [13]. Investigation of this gene
and its 5′ UTR revealed no mutations in any KM-resistant
and -susceptible strains. However, its expression level was
not determined in this study.
Previous report revealed that lack of 2′-O-methyl-
tranferase, which is encoded by tlyA and functions by
methylation of specific nucleotides in 16S rRNA and 23S
rRNA, resulted in CAP resistance [23]. Investigation of
the tlyA showed that all tested strains had the A33G sub-
stitution without any amino acid changes, suggesting that
this mutation is only nucleotide polymorphism and not
associated with the resistant phenotype. Other tlyA mu-
tations, T539G and Ins49GC, were found in two and one
CAP-resistant strains, respectively, but were not found
in all CAP-susceptible strains. These strains exhibited
the high-level resistance to CAP with MIC greater than
64 μg/ml and did not contain the rrs mutation, indicating
that these mutations were expectedly associated with
CAP resistance [24]. Most recently, the T539G has been
reported in capreomycin-resistant isolates in Korea but
with low percentage (3 out of 86, 3.5%) [38].
Conclusions
The most frequent AK- and KM-resistant mechanism in
M. tuberculosis clinical strains isolated in Thailand was
the rrs A1401G mutation (21 of 29 strains). This muta-
tion correlated with high-level resistance to both AK
and KM, and also showed cross-resistance to CAP. Mu-
tations of the eis promoter region are associated with
low-level resistance to AK and found in 5 out of 29 KM-
resistant strains. Two types of mutations at tlyA were
found in this study and might be associated with CAP
resistance. Identification of the resistant mechanisms,
particularly a novel mechanism, is important for the
development of surrogate markers that can be com-
bined with other known resistance determinants to im-
prove the rapid detection of drug-resistant M. tuberculosis
strains.
Methods
Mycobacterial strains and culture conditions
Mycobacterium tuberculosis clinical strains (one strain per
patient) were obtained from the Drug-Resistant Tuberculosis
Research Laboratory, Drug-Resistant Tuberculosis Research
Fund, Siriraj Foundation, Faculty of Medicine Siriraj
Hospital, Mahidol University. They were isolated between
2004 and 2011 from new and previously treated patients
with both known and unknown HIV status. This study
was approved by the Siriraj Ethics Committee, Mahidol
University, Bangkok, Thailand (Certificate of Approval
No. Si 208/2005). The mycobacteria were cultured on
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at 37°C for 3-4 weeks. Species identification and antimy-
cobacterial susceptibility testing were performed using
in-house one-tube multiplex PCR [39] and the standard
proportion method [40,41], respectively.
Isolation of genomic DNA
One loop of mycobacterial cells grown on solid medium
was scraped and suspended in 500 μl of TE buffer
(10 mM Tris-HCl (pH8.0), 1 mM EDTA). The cells were
inactivated by heating at 80°C for 20 min and subse-
quently harvested by centrifugation at 6,000xg at 4°C for
10 min. The cells were resuspended in 400 μl of Tris-
EDTA-Tween-lysozyme solution (10 mM Tris-HCl
(pH 8.0), 1 mM EDTA, 0.5% (v/v) Tween 80, 2 mg/ml
lysozyme (Amresco, USA)), and the mixtures were then
incubated at 37°C for 3 h. SDS and proteinase K were
added to the cell suspension to generate final concentra-
tions of 1% (w/v) and 1 mg/ml, respectively, prior to in-
cubation at 37°C for 1 h. Then, 80 μl of 5 M NaCl and
80 μl of 10% (w/v) cetyl trimethyl ammonium bromide
(CTAB) (Sigma, USA) were added to the suspension,























whiB7 (Rv3197A) F URT-whiB7 (-451) 5′-GCTGGTTCGCGGTCGGAC
R whiB7 (99) 5′-CGGGGTATCGGCGAACCA
tlyA (Rv1694) F-tlyA (1) 5′-GTGGCACGACGTGCCCGC
R-tlyA (807) 5′-CTACGGGCCCTCGCTAAT
*The first 5′nucleotide position of each primer was counted from the translation sta15 min. An equal volume of chloroform-isoamyl alcohol
(24:1) (v/v) was added to the suspension. The aqueous
DNA phase was separated by centrifugation at 12,000xg
for 5 min and mixed again with an equal volume of
chloroform-isoamyl alcohol (24:1) (v/v). DNA was precipi-
tated by adding 0.1 volume of 3 M sodium acetate (pH 5.3)
and 2.5 volumes of ice-chilled absolute ethanol, followed
by incubation at -70°C for 30 min. DNA was separated by
centrifugation at 12,000xg at 4°C for 15 min. Total nucleic
acid was washed once with 500 μl of ice-chilled 70% etha-
nol, dried, and resuspended in 20 μl of TE buffer. RNaseA
(Qiagen, Germany) was added to the total nucleic acid so-
lution to generate a final concentration of 0.5 μg/μl, and
the tube was subsequently incubated at 37°C for 1 h.
DNA amplification
The rrs (Rvnr01), eis (Rv2416c), whiB7 (Rv3197A), tap
(Rv1258c), and tlyA (Rv1694) genes were amplified by
PCR using specific primers (Table 2). PCR was performed
in a 50-μl reaction mixture containing 20 mM Tris-HCl
(pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 200 μM of each
dNTP, 0.5 μM of each primer, 50 ng of DNA template, and






CCT-3′ 51 1,680 PCR/Seq [42]
CA-3′ 53 PCR/Seq [42]
TA-3′ 54 Seq This study
TG-3′ 54 Seq This study
GA-3′ 54 Seq This study
AC-3′ 54 Seq This study
GA-3′ 60 1,661 PCR/Seq This study
GC-3′ 60 PCR/Seq This study
CC-3′ 60 Seq This study
GC-3′ 60 Seq This study
CTT-3′ 60 Seq This study
CA-3′ 60 Seq This study
TG-3′ 60 1,847 PCR/Seq This study
TC-3′ 60 PCR/Seq This study
CC-3′ 60 Seq This study
GG-3′ 60 Seq This study
GG-3′ 60 Seq This study
CC-3′ 60 Seq This study
CT-3′ 60 550 PCR/Seq This study
CA-3′ 58 PCR/Seq This study
GT-3′ 62 807 PCR/Seq This study
CG-3′ 58 PCR/Seq This study
rt codon of each gene.
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5 min, followed by 35 cycles of denaturation at 94°C for
30 sec, annealing at 56-60°C for 1 min and extension
at 72°C for 1-2 min depending on the PCR product
size (Table 2), and a final extension at 72°C for 7 min.
The PCR products were analyzed by agarose gel electro-
phoresis and purified using the QIAquick PCR Purifica-
tion Kit (Qiagen, Germany) prior to submission for DNA
sequencing.
DNA sequencing analysis
Nucleotide sequencing was performed with the Big-Dye™
Terminator Cycle Sequencing Ready Reaction Kit (Perkin
Elmer, USA) using an ABI PRISMR 3700 DNA analyzer
at First BASE Laboratories (Malaysia). The PCR products
were sequenced in both directions. The obtained nu-
cleotide sequences were compared with those of M. tuber-
culosis H37Rv (Accession no. NC_000962) by pairwise
alignment using the ClustalW program [43].
Drug susceptibility testing and determination of minimal
inhibitory concentrations (MICs)
The susceptibility testing was achieved by the disc diffusion
method on the Middlebrook 7H10 agar (Difco, USA) sup-
plemented with 10% oleic acid-albumin-dextrose-catalase
(OADC) with a single concentration of drug as rec-
ommended by the CLSI [41]. The MICs of AM, KM, and
CAP were determined by the agar dilution method accord-
ing to CLSI guidelines [41] on Middlebrook 7H10 agar
supplemented with 10% OADC and various concentrations
of drug (0, 2, 4, 8, 16, 32, and 64 μg/ml). AK, KM, and
CAP were purchased from Sigma Aldrich (Germany). The
MIC was defined as the lowest concentration of drug that
inhibited growth (>99%) after 4 weeks of incubation at
37°C. M. tuberculosis H37Rv ATCC 27294 was used as the
susceptible control strain. Three independent experiments
were performed for each strain.
Additional files
Additional file 1: Table S1. Genetic characterization of resistance genes
and MIC values for amikacin, kanamycin and capreomycin in 29 KM-resistant
clinical isolates of M. tuberculosis.
Additional file 2: Table S2. Genetic characterization of resistance genes
and MIC values for amikacin, kanamycin and capreomycin in 27 AK- and
KM-susceptible clinical isolates of M. tuberculosis.
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